Introduction
Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist
Houston Methodist Dr. Mary and Ron Neal Cancer Center
The Food & Health Alliance within the Houston Methodist Lynda K. and David M. Underwood Center for Digestive Disorders, Immunology Center and the Fondren Inflammation Collaborative
Houston Methodist Cockrell Center for Advanced Therapeutics
Paula and Joseph C. “Rusty” Walter III
Translational Research Initiative
Jerold B. Katz Academy of Translational Research
Infectious Diseases Research Fund
George and Angelina Kostas Research Center for Cardiovascular Medicine
New Endowed Chairs Positions
EnMed
Center for Bioenergetics
result
Clinical Research
Outcomes, Quality and Healthcare Performances
Restorative Medicine
Precision Medicine
Science in Service
of
Medicineresult
President's letter
2022 Metrics
Cycle of Translation
Visionary Gifts of Hope
Introduction
Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist
Houston Methodist Dr. Mary and Ron Neal Cancer Center
The Food & Health Alliance within the Houston Methodist Lynda K. and David M. Underwood Center for Digestive Disorders, Immunology Center and the Fondren Inflammation Collaborative
Houston Methodist Cockrell Center for Advanced Therapeutics
Paula and Joseph C. “Rusty” Walter III Translational Research Initiative
Jerold B. Katz Academy of Translational Research
Infectious Diseases Research Fund
George and Angelina Kostas Research Center for Cardiovascular Medicine
New Endowed Chairs Positions
EnMed
Center for Bioenergetics
From Discovery to Clinic
What is "Discovery to Clinic"?
Clinical Research
Houston Methodist Conducts First-Ever Study into a Challenging Situation
Can Regulating Cellular Aging Mitigate Both Cancer and Heart Disease?
Innovative Treatment for Chronic Rhinitis is Safe and Effective
Masters of Disguise: Glioblastomas Trick the Immune System by Masquerading as Reproductive Tissue
Improved Options for Patients with Severe Retinal Vascular Disease
A New FDA-Approved Treatment for Sufferers of Chronic Constipation
Houston Methodist joins the Gulf Coast Consortia
Outcomes, Quality and Healthcare Performance
New Findings on RNA Helicases May Yield New Intestinal Disease Therapy
Houston Methodist and Pennsylvania State University Collaborate on a Smartphone App That Could Revolutionize Stroke Diagnosis
New Frontiers to Improve Cardiovascular Medicine and Disease Management
Ongoing Lessons in a Pandemic
Transplants can Boost Survival Rate of Patients with Unresectable Liver Cancers
Telehealth Video Visits During the COVID-19 Pandemic – a Glimpse into the Future?
SARS-CoV-2 Induced Chronic Oxidative Stress and Endothelial Cell Inflammation May Increase Likelihood of Cardiovascular Diseases and Respiratory Failure
Restorative Medicine
Lessening Pain After Knee Replacement Surgery
Do Motor Neurons First Die in the Brain? Study Provides Clues about ALS Origins
Bringing Back Hand Function in People with Complete Spinal Cord Injury
Novel Vascular Engineering Platforms Are a Boon for Bioengineering
Ultra-high-Resolution Scanner Reveals if Knee Injury Advances to Osteoarthritis
Houston Methodist Model Demonstrates Reversal from Heart Failure State, Creating the Potential for Innovative Treatment Avenues
Precision Medicine
Rapidly Scalable, All-Inducible Neural Organoids Could Facilitate Drug Screening for Neurological Diseases
Importance of the Coronary Artery Calcium Score in Risk Assessment and Prevention of Atherosclerotic Cardiovascular Disease
COVID-19 Infection in Crucial Brain Regions May Lead To Accelerated Brain Aging
Interleukin 9 Secreting Polarized T Cells Show Potential in Solid and Liquid Tumor Treatment
The NanoLymph: Implantable. Adaptable. Anti-cancer
Lessening Pain After Knee Replacement Surgery
In a study, Houston Methodist researchers present clinical evidence supporting the safety and efficacy of injecting pain medication directly into the tibia during knee replacement surgery for better postoperative pain management.
The double-blind randomized trial detailed in The Journal of Arthroplasty revealed that patients receiving a mixture of morphine and the antibiotic vancomycin injected into the tibia of their knee joint have lesser pain post-surgery compared with those who did not receive the intraosseous infusion.
Kwan "Kevin" Park, MD
Francesca Taraballi, PhD
“Despite many technological advances, controlling pain after total knee arthroplasty can be challenging; most patients experience considerable pain and discomfort, especially in the first couple of weeks into their recovery,” said Orthopedic Surgeon Kwan “Kevin” Park, MD. “Intraosseous infusion allows us to control pain preemptively so that patients don't have to take as much pain medicine later on.”
Total knee replacement is the recommended treatment to alleviate chronic pain caused by damage to the knee joint from arthritis or injury. According to the 2021 American Joint Replacement Registry Annual Report, primary knee replacement surgeries accounted for 54.5% of the nearly 2 million hip and knee replacement procedures performed between 2012 and 2020.
Despite the high frequency and favorable outcomes of the surgical procedure, the manipulation of soft tissue and resurfacing damaged bones during knee replacement causes pain in the early postoperative periods.
By infusing pain medication intraosseously, we're able to reduce postoperative pain for up to two weeks, the number of pain pills patients need, and even possibly improve the function of the knee over time
Kwan "Kevin" Park, MD
“Twenty years ago, patients would remain in the hospital for several days after their surgery and receive extremely high-dose narcotics to help with their postoperative pain,” said Park. “But there has been a paradigm shift; patients are often discharged the same day after knee replacement surgery, and we use multimodal pain management techniques that work much better for pain control and require fewer narcotics.”
These multimodal regimens, he added, often include a combination of medications, such as nonsteroidal anti-inflammatory drugs, opioids and neurogenic agents, administered both preemptively and after the surgery. However, opioid medications, although very effective in managing pain, have known side effects, like constipation and nausea. In addition, some people are even allergic to opiates. Furthermore, a consensus on the optimal preoperative protocol to mitigate pain is lacking.
Previously, the researchers demonstrated that injecting vancomycin directly into the tibia before surgery helped in reducing infection by reaching a higher concentration of the drug in the knee. Motivated by this success, they investigated whether delivering both morphine and vancomycin into the tibial bone could improve postoperative pain management.
For the study, the team included 48 patients needing total knee replacement surgery. Of these patients, half were randomly assigned to receive vancomycin and morphine intraosseously using an infusion device that was inserted into the tibial tubercle region. The remaining were only administered vancomycin. The researchers then monitored patient-reported pain, nausea and opioid use for up to 14 days after surgery. Also, Park’s team collaborated with Francesca Taraballi, PhD, Assistant Professor of Orthopedic Surgery and Director of the Center for Musculoskeletal Regeneration, to measure the serum levels of morphine and the inflammatory marker interleukin-6 in all study participants for 10 hours after the operation.
Upon analyzing their data, the researchers found that the patients who were given morphine in the tibial bone had lower pain scores after their knee replacements compared to those who did not. Further, these patients also reported having less pain for several days and had similar serum interleukin-6 levels as the control group. Taken together, although the patients who received pain medication intraosseously had comparable inflammation, these patients were taking less pain medication post-surgery.
The researchers have published the findings of the double-blind randomized controlled trial in The Journal of Arthroplasty.
Park noted that the intraosseous infusion of opiates could potentially even facilitate a swift recovery of the knee joint.
“By infusing pain medication intraosseously, we're able to reduce postoperative pain for up to two weeks, the number of pain pills patients need, and even possibly improve the function of the knee over time,” he said. “Our technique can also improve the multimodal pain management protocol we have been using for knee replacement over the years.”
More from Discovery to Clinic